NCT06712875: MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 27 planned
- Started
- 1 Apr 2025
- Primary completion
- Dec 2028
- Arms
- Dabrafenib + trametinib combined with nivolumab (Cohort B)
- Results
- None posted
- 2 Dec 2024: Trial registered
- 1 Apr 2025: Trial started